We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

186 hedge funds and large institutions have $466M invested in PDL BioPharma, Inc. in 2017 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 63 increasing their positions, 44 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 13

45% more capital invested

Capital invested by funds: $321M → $466M (+$145M)

43% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 44

9% more funds holding

Funds holding: 171 → 186 (+15)

37% less call options, than puts

Call options by funds: $450K | Put options by funds: $717K

Holders
186
Holders Change
+15
Holders Change %
+8.77%
% of All Funds
4.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
63
Reduced
44
Closed
13
Calls
$450K
Puts
$717K
Net Calls
-$267K
Net Calls Change
-$555K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$8.55M
2
Morgan Stanley
Morgan Stanley
New York
+$6.49M
3
State Street
State Street
Massachusetts
+$5.81M
4
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$3.96M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.56M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$9.56M
2
Bank of America
Bank of America
North Carolina
-$4.6M
3
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
-$3.61M
4
BlackRock
BlackRock
New York
-$2.18M
5
Deutsche Bank
Deutsche Bank
Germany
-$2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
126
Squarepoint
New York
$79K +$64.5K +23,214 New
SEI Investments
127
SEI Investments
Pennsylvania
$78K +$63.3K +22,761 +5,634%
FSA
128
Franklin Street Advisors
North Carolina
$76K – – –
B
129
BancorpSouth
Mississippi
$74K – – –
LTFS
130
Ladenburg Thalmann Financial Services
Florida
$71K – – –
Axa
131
Axa
France
$70K +$57.6K +20,700 New
AB
132
Amalgamated Bank
New York
$67K -$1.2K -432 -2%
CAN
133
Cetera Advisor Networks
California
$62K – – –
DIA
134
Denver Investment Advisors
Colorado
$58K +$47.4K +17,029 New
Canada Life
135
Canada Life
Manitoba, Canada
$55K – – –
NA
136
Nottingham Advisors
New York
$54K – – –
SBIA
137
Sheaff Brock Investment Advisors
Indiana
$54K +$8.34K +3,000 +23%
OC
138
Oppenheimer & Co
New York
$51K – – –
TCM
139
Traynor Capital Management
Pennsylvania
$51K – – –
LOAME
140
Lombard Odier Asset Management (Europe)
United Kingdom
$50K – – –
FDCDDQ
141
Federation des caisses Desjardins du Quebec
Quebec, Canada
$50K – – –
Envestnet Asset Management
142
Envestnet Asset Management
Illinois
$49K +$37.8K +13,579 +1,929%
AWA
143
Arete Wealth Advisors
Illinois
$47K +$38.2K +13,746 New
Ameriprise
144
Ameriprise
Minnesota
$47K +$38.8K +13,949 New
GC
145
Gratus Capital
Georgia
$44K – – –
Teacher Retirement System of Texas
146
Teacher Retirement System of Texas
Texas
$43K -$220 -79 -0.6%
3C
147
361 Capital
Colorado
$43K +$35.2K +12,666 New
RJA
148
Raymond James & Associates
Florida
$40K +$32.4K +11,667 New
AIP
149
Ameritas Investment Partners
Nebraska
$39K – – –
SRC
150
Shufro Rose & Co
New York
$39K – – –
4 5
6
7 8

PDLI Hedge Fund Activity: Q3 2017 in Review

186 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2017, worth a combined $466M — up 45% from $321M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new PDLI positions and 13 closed out — a net gain of 18 holders — while 63 added to existing stakes and 44 trimmed.

The largest buyer was Millennium Management, adding an estimated $8.55M. The largest seller was Citadel Advisors, cutting an estimated $9.56M.

  • 186 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2017, up from 171 in Q2 2017.
  • Funds reported $466M of PDL BioPharma, Inc. stock for Q3 2017, up 45% quarter-over-quarter.
  • 31 funds opened new PDL BioPharma, Inc. positions in Q3 2017 and 13 closed out, a net change of +18 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2017 was Millennium Management, an estimated $8.55M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2017 was Citadel Advisors, an estimated $9.56M sold.

Based on aggregated 13F filings for Q3 2017.